News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingView Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Jabil, Inc. (NYSE:JBL) has received a consensus "Buy" rating from ten brokerages, with an average 12-month price target of $453.67. The company recently surpassed quarterly expectations with $3.16 EPS and $8.75 billion in revenue, an 11.8% year-over-year increase. Institutional investors hold 93.39% of Jabil's …
This article provides an analysis of Abivax Sa (NASDAQ: ABVX), highlighting a weak near-term sentiment but potential long-term strength. It details specific AI-generated trading strategies including long, breakout, and short positions, along with support and resistance levels across different time horizons. The analysis suggests …
The article provides information related to Parabilis Medicines (PBLS) stock options chain, including quotes and news. The content itself is not available in the provided input.
Athira Pharma (NASDAQ:LONA) reported quarterly earnings of ($0.80) per share, significantly beating the consensus estimate of ($1.90). Following the announcement, shares rose 1.4% to $7.98. Analysts maintain a "Moderate Buy" rating with a $16 price target, and institutional investors hold 57.12% of the company's …
Shares of Jabil Inc. (JBL) fell 1.94% on Friday, closing at $363.10. This underperformance occurred during a generally poor trading session where the S&P 500 Index and Dow Jones Industrial Average also declined. The stock's drop ended a three-day winning streak for Jabil Inc.
This article provides a detailed overview of Jabil Inc (JBL) stock, including its current price, market performance, key financial figures, and analyst ratings. Jabil Inc's stock score is -0.02, with a target price of $426.544, indicating a "Buy" rating from analysts. The company specializes …
TCG Crossover investment entities and Chen Yu have reported a significant stake in Abivax (ABVX) through American Depositary Shares (ADSs). TCG Crossover Fund I, L.P. and its general partner hold 5.7% of Abivax's ordinary shares, while TCG Crossover Fund II, L.P. holds 1.3%. Chen …
ARCH Venture Fund XII and related entities have disclosed a 5.3% beneficial ownership stake in Parabilis Medicines (PBLS), amounting to 6,412,780 shares of common stock. This Schedule 13G filing indicates a passive investment, with ARCH Venture Partners XII, L.P., ARCH Venture Partners XII, LLC, …
IM Cannabis press release [https://seekingalpha.com/filing/309949813] (IMCC [https://seekingalpha.com/symbol/IMCC]): Q2 revenue of $7.6 million, compared to $12.7 million in the same period in 2025. * Gross profit of $1.5 million, compared to $3.4 million in the same period in 2025. * Operating loss of $2.1 million, …
Anheuser-Busch InBev SA/NV BUD, popularly known as AB InBev, delivered encouraging volume performance in the second quarter of 2026, signaling improving momentum across its global business. The company benefited from market share gains, continued investment in its megabrands and growth across emerging markets. Management …
Parabilis Medicines, Inc. reported its Q2 2026 results, showing a significant increase in cash and cash equivalents to over $1.1 billion. This boost follows its June 2026 IPO, which generated $787.9 million in net proceeds, and a $50.0 million upfront payment from its collaboration …
The article is a brief financial news item from Investing.com, reporting on a Form 8K filing by Parabilis Medicines for August 13th. It provides no further details beyond stating the filing occurred on that date.
Parabilis Medicines, Inc. (PBLS) reported its Q2 revenue as $148,000. The company, a clinical-stage biopharmaceutical firm, focuses on developing transformative medicines for "undruggable" protein targets using its proprietary Helicon platform. Analysts currently have a "BUY" consensus for PBLS with an average target price of …
IM Cannabis Corp. reported a significant revenue decrease in Q2 2026, falling to $7.6 million from $12.7 million in Q2 2025, alongside a net loss of $4.4 million. The company is facing ongoing financial challenges, including increased operating losses and a growing shareholders' deficit. …
IM Cannabis Corp. (IMCC) reported a significant decline in Q2 2026 revenue, down 42.8% year-over-year to $5.4 million, with a net loss of $3.1 million. This financial performance led to a 1.9% drop in the stock price after market close. Institutional investors showed mixed …
IM Cannabis Corp. (IMCC) reported a significant revenue drop and mounting losses for the first half of 2026, leading management to flag substantial doubt about the company's ability to continue as a going concern. Revenue fell to $16.268 million from $25.196 million year-over-year, with …
Search by ticker symbol or company name and select a result to open its chart.